All Posts By

Smartkarma Daily Briefs

Daily Brief Industrials: Mazda Motor, Rainbow Robotics, Triumph Group and more

By | Daily Briefs, Industrials

In today’s briefing:

  • Unloved Japan Round Up Jan. 3: Set Up for A Banner Year?
  • Samsung Group ETF Rebalancing Event to Watch for in June
  • Triumph Group’s Solid Cost-Cutting Efforts Skyrocket EBITDA Margins! – Major Drivers


Unloved Japan Round Up Jan. 3: Set Up for A Banner Year?

By Michael Allen

  • 2025 will start with more attractive turnaround opportunities than we have seen in a long time. 
  • An uptick in TOBs, MBOs and merger discussions makes it suddenly no longer safe to short low-PBR companies indiscriminately.
  • Investors are noticing. More than two-dozen large- and medium-cap stocks with deep discounts to the benchmark began to bounce off well-defined support levels in late December.

Samsung Group ETF Rebalancing Event to Watch for in June

By Sanghyun Park

  • With Samsung finalizing the call option on Rainbow Robotics in February, the FTC will add it to Samsung Group in March, ensuring its inclusion in the ETF by June.
  • With the market cap boost from the call option, Rainbow Robotics is set to easily exceed 2% weight in the ETF by June.
  • The rebalancing from June 2-9 will direct 30% of daily volume into Rainbow Robotics, likely enough to move the needle on price action, especially on the first day.

Triumph Group’s Solid Cost-Cutting Efforts Skyrocket EBITDA Margins! – Major Drivers

By Baptista Research

  • Triumph Group presented a mix of performance outcomes in its second quarter fiscal 2025 results.
  • The company demonstrated a commendable increase in its aftermarket growth, which surged 13% year-over-year and contributed over 60% to its profit.
  • This was achieved through robust spares and repairs activities within both commercial and military sectors, setting a positive trend amid some broader market challenges.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Health Care: Orum Therapeutics, CytoSorbents , Masimo Corp, Neurocrine Biosciences, Seres Therapeutics, Stevanato Group SpA and more

By | Daily Briefs, Healthcare

In today’s briefing:

  • Orum Therapeutics Lowers IPO Price Range
  • CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.
  • Masimo Corporation: Here Are the 6 Most Critical Factors Shaping Its Performance in 2025 & Beyond! – Major Drivers
  • Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers
  • Seres Therapeutics: Will Its Strategic Partnerships & Collaborations Prove to Be a Game-Changing Move?
  • Stevanato Group: Engineering Optimization For A Competitive Edge But Will It Work? – Major Drivers


Orum Therapeutics Lowers IPO Price Range

By Douglas Kim

  • Orum Therapeutics (475830 KS) has lowered its IPO price range to 24,000 won to 30,000 won.
  • The IPO offering amount will be between 60 billion won to 75 billion won. The expected market cap of the IPO is between 531 billion won to 664 billion won. 
  • Our updated valuation of Orum Therapeutics suggests implied target price of 24,939 won per share, which is 8% lower than the mid-point of the revised down IPO price range. 

CTSO: CytoSorbents reports preliminary 4th quarter and 2024 financial results which showed impressive growth in the core international business that exceeded our expectations.

By Zacks Small Cap Research

  • CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive care unit and cardiac surgery.
  • The company also seeks U.S. and Canadian approval of a second product, DrugSorb-ATR, to reduce perioperative bleeding risk in patients on blood thinners during cardiac surgery.
  • Based on the results of its pivotal U.S. and Canadian STAR-T trial, the company submitted for FDA De Novo approval on September 27, 2024, and Health Canada on November 1, 2024, with regulatory decisions expected in 2025.

Masimo Corporation: Here Are the 6 Most Critical Factors Shaping Its Performance in 2025 & Beyond! – Major Drivers

By Baptista Research

  • Masimo Corporation, a global technology company focused on experienced healthcare solutions, recently reported its financial results for the third quarter of 2024.
  • The company’s healthcare segment demonstrated robust performance, with revenues reaching $343 million, showcasing a 12% year-over-year growth.
  • This growth was attributed to increased consumable and service revenues, although partially offset by a decline in capital equipment sales.

Neurocrine Biosciences: Commercial Expansion & Market Penetration Underpinning Our ‘Outperform’ Rating! – Major Drivers

By Baptista Research

  • Neurocrine Biosciences has presented its third-quarter 2024 results, highlighting both achievements and ongoing strategic initiatives.
  • Under the new leadership of CEO Kyle Gano, the company is focusing on strengthening its position as a leading neuroscience organization.
  • Its revenue growth has been particularly driven by the performance of its drug INGREZZA, with an impressive $613 million in sales this quarter, translating to 25% year-over-year growth.

Seres Therapeutics: Will Its Strategic Partnerships & Collaborations Prove to Be a Game-Changing Move?

By Baptista Research

  • Seres Therapeutics has outlined significant developments and strategic decisions during its third-quarter 2024 update.
  • The company achieved notable milestones, primarily around its lead clinical candidate, SER-155, and its corporate financial structure, significantly influenced by the sale of its VOWST program to Nestlé Health Science.
  • Seres reported positive data from its Phase Ib clinical trial for SER-155, indicating a potential for reducing bacterial bloodstream infections (BSIs) in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

Stevanato Group: Engineering Optimization For A Competitive Edge But Will It Work? – Major Drivers

By Baptista Research

  • Stevanato Group’s third-quarter 2024 financial results present a complex picture that warrants a balanced examination of both its organizational strategies and market dynamics.
  • The company reported a modest 2% revenue growth year-over-year, slightly tempered by persistent challenges in its Engineering segment and vial destocking effects.
  • These factors influenced management’s decision to lower the full-year 2024 guidance for adjusted EBITDA and adjusted diluted EPS.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Consumer: Viva Goods , FreshKet, Mojave Energy Systems, Tri Pointe Group, TSE Tokyo Price Index TOPIX and more

By | Consumer, Daily Briefs

In today’s briefing:

  • Bossini (592 HK): 10th Feb Scheme Vote
  • Freshket raises US$8M in a funding round led by Thai President Foods, Kliff Capital | e27
  • Earth Venture Capital backs Mojave Energy Systems in US$9.5M Series A funding | e27
  • Tri Pointe Homes: A Strong Liquidity Position Can Fuel Expansion! – Major Drivers
  • FSA Roadmap Is Realistic, but Progress on Scope 3 Disclosures Will Follow the Revision of Guidelines


Bossini (592 HK): 10th Feb Scheme Vote

By David Blennerhassett

  • On the 16th October, Li Ning-backed Viva Goods (933 HK)  announced a scrip Offer, by way of a Scheme, for 62.91%-held Bossini International Holdings (592 HK), a casual apparel play.
  • One new Viva share for five Bossini shares backed an implied scrip price of HK$0.108/share, a 12.2% discount to undisturbed. 
  • Bossini’s Scheme Doc is now out, with a Court Meeting on the 10th February, and expected  settlement on the 24th March. The IFA says “fair and reasonable”. 

Freshket raises US$8M in a funding round led by Thai President Foods, Kliff Capital | e27

By e27

  • Thailand-based Freshket announced that it has raised an additional US$8 million funding round led by led by Thai President Foods or TFMAMA and Kliff Capital with continued support from existing investors, including Openspace and ECG Venture Capital.
  • In a press statement, a TFMAMA spokesperson said that the company hopes to support Freshket through the provision of fresh and quality ingredients for the startup’s operations following this funding round.
  • “We are currently expanding into new markets and customer segments while maintaining our existing customer base.

Earth Venture Capital backs Mojave Energy Systems in US$9.5M Series A funding | e27

By e27

  • Earth Venture Capital, a global climate tech firm backing deep-tech startups to decarbonise Emerging Asia, announced its participation in Mojave Energy Systems’ US$9.5 million Series A funding round.
  • The investment, alongside the participation of Fifth Wall, At One Ventures, Myriad Venture Partners, Starshot Capital, and Alumni Ventures Group, raises Mojave’s total funding to US$25.6 million.
  • In the next phase of innovation, Mojave plans to unveil ArctiDry HP, the first air conditioning system to integrate liquid desiccant technology with a reversible heat pump.

Tri Pointe Homes: A Strong Liquidity Position Can Fuel Expansion! – Major Drivers

By Baptista Research

  • Tri Pointe Homes’ (TPH) latest financial results for the third quarter of 2024 present a combination of robust performance metrics and strategic market positioning, alongside noted challenges in certain geographies and market segments.
  • As a residential home builder operating across diverse U.S. markets, Tri Pointe achieved notable gains in home deliveries, revenue growth, and profitability, yet remains vigilant of macroeconomic and regional headwinds impacting future outlook.
  • Baptista Research looks to evaluate the different factors that could influence the company’s price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

FSA Roadmap Is Realistic, but Progress on Scope 3 Disclosures Will Follow the Revision of Guidelines

By Aki Matsumoto

  • An assurance system will be established to ensure the quality of assurance. The assurance provider is expected to be a profession-agnostic system that is not limited to auditing firms.
  • The assurance will be limited to Scope 1 and 2, and only Scope 1 and 2, which most large companies already disclose, will be initially required to be disclosed.
  • Scope 3 disclosures have not progressed at this time, but Scope 3 disclosures are expected to progress after the safe harbor is included and the disclosure guidelines are revised.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Financials: Get Nice Financial Group Ltd, Admiral, Hongkong & Shanghai Hotels and more

By | Daily Briefs, Financials

In today’s briefing:

  • Get Nice Financial (1469 HK): EGM Set For Get Nice (64 HK)’s Scrip Offer
  • Admiral Group Plc (AMIGY) – Thursday, Oct 3, 2024
  • The Hongkong & Shanghai Hotels (45 HK)


Get Nice Financial (1469 HK): EGM Set For Get Nice (64 HK)’s Scrip Offer

By David Blennerhassett

  • On the 5th November, Get Nice Holdings (64 HK) (GNH) announced a scrip Offer, by way of a Scheme, for 72.99%-held Get Nice Financial Group Ltd (1469 HK) (GNF).
  • With an implied scrip price & divvy of HK$1.116/share, against a book value of HK1.736/share – and net cash of ~HK$1.00/share – this is probably being down too cheaply.
  • GNH’s Circular is now out, with an EGM to be held on the 22nd Jan. GNF’s Scheme Doc is expected to be dispatched one or before the 10th Feb. 

Admiral Group Plc (AMIGY) – Thursday, Oct 3, 2024

By Value Investors Club

  • Admiral shares have shown strong performance with a 13% CAGR since May 2018 and reaching all-time-highs after 1H24 results
  • Despite recent pullbacks, Admiral’s market cap of £8.6bn is considered very cheap
  • The market underestimates Admiral’s potential, with the business transitioning from a “sell” to a “buy” consensus in recent years and earnings upgrades through 2024

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


The Hongkong & Shanghai Hotels (45 HK)

By Michael Fritzell

  • Great portfolio of assets, most notably 10 hotels under the Peninsula brand name
  • Capex has been excessive over the past 10 years, especially in London, but the company is now focused on execution and paying back debt. Both London and Istanbul ramping up.
  • NAV per share of HK$24 per share, putting at the HK$6.2 price at a 74% discount to NAV. Key is whether Philip Kadoorie will unlock value once he takes over.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Private Markets: Eureka Robotics raises US$10.5M to power the future of factory automation | e27 and more

By | Daily Briefs, Private Markets

In today’s briefing:

  • Eureka Robotics raises US$10.5M to power the future of factory automation | e27
  • Funding Societies raises US$25M to further expand payments business in SEA | e27


Eureka Robotics raises US$10.5M to power the future of factory automation | e27

By e27

  • Singapore-based Eureka Robotics has raised US$10.5 million in Series A financing.
  • B Capital spearheaded the round. New investors Airbus Ventures, Maruka Corporation, and G. K. Goh Ventures participated along with existing investors UTEC and ATEQ.
  • Eureka Robotics was founded in 2018 to enable factories worldwide to automate dull, dirty, and dangerous tasks. The company leverages its proprietary technologies, which include high-accuracy calibration, computer vision, motion planning, and force control.

Funding Societies raises US$25M to further expand payments business in SEA | e27

By e27

  • Digital finance platform Funding Societies | Modalku (Funding Societies) today announced that it has raised US$25 million in equity investment from Japan’s sovereign wealth fund Cool Japan Fund (CJF), marking the fund’s first investment into a fintech company in Southeast Asia (SEA).
  • The company said it will funnel the investment to deepen its core business in SME financing across its five markets (Singapore, Indonesia, Malaysia, Thailand and Vietnam) whilst further expanding its payments business since embarking on it in 2022.
  • In a press statement, Funding Societies said it will focus on helping businesses get paid faster through innovative receivables and financing solutions. It will also leverage technology and AI to digitise and automate lending origination processes.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Quantitative Analysis: Hong Kong Connect Flows (December): $10.7bn Inflows Led by Banks and more

By | Daily Briefs, Quantitative Analysis

In today’s briefing:

  • Hong Kong Connect Flows (December): $10.7bn Inflows Led by Banks


Hong Kong Connect Flows (December): $10.7bn Inflows Led by Banks

By Ke Yan, CFA, FRM

  • We analyze the monthly Hong Kong Connect flows with our data engine.
  • We tabulate the top stocks by inflows, outflows, and holding by mainland investors.
  • We highlight inflows into CCB, Alibaba, China Mobile, ICBC, ABC.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief ECM: Bloks Group IPO (0325.HK): Global Offering and more

By | Daily Briefs, ECM

In today’s briefing:

  • Bloks Group IPO (0325.HK): Global Offering, The Initial Price Range Is Seen As Attractively Valued
  • Bloks Group IPO – PHIP Updates – Momentum Remains Strong, Although Some Lingering Doubts Persist
  • LG CNS IPO: The Bear Case
  • Pre-IPO Ascentage Pharma – The US Stock Listing Will Stimulate Future Growth Potential


Bloks Group IPO (0325.HK): Global Offering, The Initial Price Range Is Seen As Attractively Valued

By Andrei Zakharov

  • Shanghai-Based Bloks Group, a leader of assembly character toys in China, has announced the initial price range for its IPO in Hong Kong.
  • The offering is expected to be between HK$55.65 and HK$60.35, implying a market cap of ~HK$14B or ~$1.8B at the midpoint of the price range. 
  • Assuming IPO offer price of HK$58.00, UBS AM Singapore, Greenwoods AM and Fullgoal Investors have agreed to invest ~HK$388M or ~$50M in the offering.

Bloks Group IPO – PHIP Updates – Momentum Remains Strong, Although Some Lingering Doubts Persist

By Clarence Chu

  • Bloks Group (1850960D CH) is looking to raise US$188m in its Hong Kong IPO.
  • Bloks Groups (Bloks) operates in the toy segment where it primarily assembles character and brick-based toys.
  • In our previous note, we looked at the firm’s past performance. In this note, we discuss the latest PHIP updates.

LG CNS IPO: The Bear Case

By Arun George

  • LG CNS (LGCNSZ KS), the IT service unit of LG Corp (003550 KS), seeks to raise up to US$837 million through a primary/secondary offering.
  • In LG CNS IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The bear case rests on fading growth momentum, mid-tier revenue growth, weak non-AI growth, high contract assets, bottom-tier FCF margin and large share overhang. 

Pre-IPO Ascentage Pharma – The US Stock Listing Will Stimulate Future Growth Potential

By Xinyao (Criss) Wang

  • Ascentage has filed with the SEC to raise up to US$100 million in a US IPO. We think its future market value is expected to surpass that of Hutchmed.
  • The outlook of olverembatinib is clear. Takeda can give more possibilities to olverembatinib. 2025 Sales of olverembatinib is expected to reach RMB500 million.Market value contribution from olverembatinib is US$1-1.5 billion. 
  • Investors have higher expectations on APG-2575 to be out-licensed to MNCs. We think the peak sales of APG-2575 is expected to surpass that of olverembatinib in overseas markets. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Thematic (Sector/Industry): US Banks – Weekly Loans Surge at Large Banks and more

By | Daily Briefs, Thematic (Sector/Industry)

In today’s briefing:

  • US Banks – Weekly Loans Surge at Large Banks, With -Ve YoY Growth CRE, Jumbo Deposits Down
  • #78 India Insight: Jio’s ₹40,000 Cr IPO, Eicher Motors’ 7% Rev Growth, and VI’s 5G Rollout


US Banks – Weekly Loans Surge at Large Banks, With -Ve YoY Growth CRE, Jumbo Deposits Down

By Daniel Tabbush

  • Weekly HFD for large US banks shows a profit-positive picture in latest data through 18 December
  • Loan growth is accelerating in the week and in the past few weeks, with a steady rise in the pace of growth since late November
  • Where large US banks are growing loans more aggressively, but seeing more negative growth in higher cost Jumbo Deposits, this can be highly positive for core income

#78 India Insight: Jio’s ₹40,000 Cr IPO, Eicher Motors’ 7% Rev Growth, and VI’s 5G Rollout

By Sudarshan Bhandari

  • Reliance Jio plans a Rs. 40,000 crore IPO, with pre-IPO placements underway, leveraging AI, satellite internet, and 5G growth.
  • Eicher Motors posts 7% revenue growth, despite slight dip in Royal Enfield sales, with a strategic foray into electric vehicles.
  • VI plans aggressive 5G rollout with 15% discounted entry-level plans, targeting 75 cities and aiming to rebuild its subscriber base.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Event-Driven: Sun Art Retail (6808 HK): BABA Takes Massive Hit After Inking SPA @ HK$1.38 and more

By | Daily Briefs, Event-Driven

In today’s briefing:

  • Sun Art Retail (6808 HK): BABA Takes Massive Hit After Inking SPA @ HK$1.38
  • Canvest (1381 HK): Attractive Spread with Steady Progress in Precondition Satisfaction
  • NZ: Contact Energy (CEN NZ) Hotter Than Mercury (MCY NZ) As Catalyst Looms
  • EQD | KOSPI 200 Index – Buy January Straddle


Sun Art Retail (6808 HK): BABA Takes Massive Hit After Inking SPA @ HK$1.38

By David Blennerhassett

  • HK$1.38/Share. That’s the takeaway as Alibaba Group (9988 HK) enters an SPA to offload its 78.7% stake in Sun Art (6808 HK) at HK$1.38/share, a 44.4% discount to last close.
  • The buyer, Paragon Shine, an entity under Chinese PE outfit DCP Capital, is paying ~HK$12.3bn compared to BABA’s HK$28.1bn purchase of a 51% stake in October 2020.
  • Should the SPA complete, an unconditional MGO is triggered. Minorities tendering can receive up to HK$1.58/share. But the question is: why would BABA be cashing out at this price?

Canvest (1381 HK): Attractive Spread with Steady Progress in Precondition Satisfaction

By Arun George

  • Grandblue Environment Co A (600323 CH) continues to make steady progress in satisfying the precondition for its HK$4.90 privatisation offer for Canvest Environmental Protection Group (1381 HK)
  • Two of the five preconditions are satisfied, and another will be satisfied by 20 January. The long stop date of 17 July provides ample time to satisfy the remaining two. 
  • Although the peers have materially re-rated, the offer implies a premium compared to peer multiples. Vote risk remains low, aided by selling by a shareholder with a blocking stake. 

NZ: Contact Energy (CEN NZ) Hotter Than Mercury (MCY NZ) As Catalyst Looms

By Brian Freitas


EQD | KOSPI 200 Index – Buy January Straddle

By John Ley

  • The implied move for January is less than what has been historically experienced. Sixteen of the last 26 years have had price movement > current implied move.
  • January punches above its weight in terms of both historic volatility (most volatile month) and the amount of price movement relative to that historic volatility.
  • Trades at the current implied move historically would have been winners 61.5% of the time with the average winner being more than double the average loser. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief Equity Bottom-Up: Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 1Q 2025 and more

By | Daily Briefs, Equity Bottom-Up

In today’s briefing:

  • Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 1Q 2025
  • Palantir’s Influence on the Political Rallies in Korea & HD Hyundai’s 34% Stake in Palantir Korea
  • Adient Plc: Growth in Asia-Pacific Markets Fueling Our Optimism! – Major Drivers
  • The Beat Ideas: MSTC- An E-Commerce PSU
  • Philippine Stock Exchange (PSE PM): A Detailed Analysis Of Two Value Doubling Catalysts
  • Inspire Medical Systems: Is The New Inspire V System A Game Changer? – Major Drivers
  • Kering: It’s Gucci – [Business Breakdowns, EP.199]
  • Samsonite (1910) – Friday, Oct 4, 2024
  • Alpha Metallurgical Resources: Market Adaptation & Product Diversification As A Strategic Growth Enabler! – Major Drivers
  • Monthly Sales Overview of Indian Listed Tractor Companies (December 2024)


Gap Trade Opportunities in Korean Prefs Vs Common Share Pairs in 1Q 2025

By Douglas Kim

  • In this insight, we discuss numerous gap trade opportunities involving Korean preferred and common shares in 1Q 2025.
  • Among the 27 major pair trades (prefs vs. common shares), 20 of the pref stocks outperformed their common shares counterparts in 2024.
  • The 27 Korean preferred stocks’ average prices declined by 1% from end of 2023 to end of 2024 (excluding dividends), outperforming their common counterparts which were down on average 3.7%.

Palantir’s Influence on the Political Rallies in Korea & HD Hyundai’s 34% Stake in Palantir Korea

By Douglas Kim

  • In this insight, we discuss the increasing importance of Palantir Technologies (PLTR US) on influencing the political rallies in Korea. 
  • In addition, we discuss how HD Hyundai’s 34% ownership of Palantir Korea is likely to improve the positive sentiment on HD Hyundai. 
  • Our sum-of-the-parts valuation analysis of HD Hyundai suggests implied market cap of 11 trillion won or target price of 139,845 won per share (63% upside from current levels).

Adient Plc: Growth in Asia-Pacific Markets Fueling Our Optimism! – Major Drivers

By Baptista Research

  • Adient plc has recently reported its fourth quarter 2024 earnings as well as its full-year results, providing a snapshot of the company’s current position and future outlook.
  • The company’s performance was solid in the face of a challenging macroeconomic environment.
  • Revenues decreased by 4% year-over-year, but Adient managed to maintain adjusted EBITDA at $235 million, highlighting its ability to mitigate customer volume headwinds through strong business performance.

The Beat Ideas: MSTC- An E-Commerce PSU

By Nimish Maheshwari

  • MSTC Limited (MSTCLTD IN) is transitioning to an e-commerce-centric model, reducing dependence on trading sales and focusing on high-margin e-commerce services.
  • MSTC sold its subsidiary Ferro Scrap Nigam Limited for an amount of Rs. 300 Crores which will be utilised in the near future.
  • MSTC has a strong cash position (Rs. 1,300 Cr) that can be used for special dividends, growth-oriented investments, or share buyback programs.

Philippine Stock Exchange (PSE PM): A Detailed Analysis Of Two Value Doubling Catalysts

By Sameer Taneja

  • In its press release on December 26th, the Philippine Stock Exchange (PSE PM) detailed two catalysts: acquiring 61.92% of PDS and increasing the listing maintenance fee. 
  • The PDS (Philippine Dealing System) pricing of 2.32 billion pesos for 61.92% implies a 10.5x PE (7.5x PE ex-cash), which will be accretive to earnings despite the cash coming down. 
  • With the 75% increase in the upper limit of listing and maintenance fees and the acquisition, the stock trades at 12-13x PE/7.6% dividend yield and three billion net cash.

Inspire Medical Systems: Is The New Inspire V System A Game Changer? – Major Drivers

By Baptista Research

  • Inspire Medical Systems reported a promising third quarter in 2024, demonstrating significant revenue growth and improvements in profitability.
  • The company’s revenue for the third quarter was $203.2 million, up 33% compared to the same period in 2023.
  • This growth was predominantly driven by the increased adoption of Inspire therapy, reflected in the expansion into 66 new implanting centers and growth in 13 new U.S. sales territories.

Kering: It’s Gucci – [Business Breakdowns, EP.199]

By Business Breakdowns

  • Kering is a luxury house similar to LVMH, with brands like Gucci, YSL, Bottega Veneta, and Balenciaga
  • Gucci represents nearly 50% of Kering’s revenues and over 50% of profits, with its popularity tied to fashion trends
  • Kering traces its history back to a diverse set of regional businesses before focusing on luxury under the leadership of Francois Henry Pinault

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only.


Samsonite (1910) – Friday, Oct 4, 2024

By Value Investors Club

  • Samsonite is planning to re-list in the US, despite currently being listed in Hong Kong
  • Company is trading at low valuation but expected to see medium-term growth
  • Listing in Hong Kong has not benefitted Samsonite, with potential for increased interest and growth in the US market

This content is sourced through publicly available sources and has been machine generated. Information displayed is for general informational purposes only. This article was originally published 3 months ago on Value Investors Club.


Alpha Metallurgical Resources: Market Adaptation & Product Diversification As A Strategic Growth Enabler! – Major Drivers

By Baptista Research

  • Alpha Metallurgical Resources reported its third quarter 2024 financial results, indicating a challenging period due to decreased coal pricing and unfavorable market conditions.
  • The company posted an adjusted EBITDA of $49 million and shipped 4.1 million tons of coal during the quarter.
  • These figures were negatively influenced by lower coal prices, soft market demand, and certain operational challenges such as difficult geology and weather conditions.

Monthly Sales Overview of Indian Listed Tractor Companies (December 2024)

By Sreemant Dudhoria

  • Favorable reservoir level, an uptick in Kharif Harvest, and strong sowing for the Rabi season are expected to drive good demand for tractors in the medium term.
  • We summarize the sales volume published by listed players Mahindra & Mahindra(M&M), and Escorts Kubota Limited.
  • Positive management commentary augurs well for uptick in tractor OEM stocks and related auto ancillary companies like GNA Axles Ltd (GNA IN) in medium term.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars